SCHEMBL7047704

SCHEMBL7047704

CC(C)=CCc1c(-c2ccccc2O)oc2ccccc2c1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.59
▸ VKORC1 Q9BQB6 2/20 0.59
▸ PDE4D Q08499 2/20 0.53
▸ PTPN1 P18031 4/20 0.50
▸ NUDT1 P36639 2/20 0.50
▸ RELA Q04206 2/20 0.50
▸ BCHE P06276 1/20 0.48
▸ ACHE P22303 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ BACE1 P56817 1/20 0.48
▸ CYP19A1 P11511 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ NMUR2 Q9GZQ4 1/20 0.45
▸ TYR P14679 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2428081 0.85 NMUR2 (0.47) IKBKBPTPN1KDM4EMEN1ALDH1A1
SCHEMBL623887 0.83 VKORC1 (0.59) IKBKBVKORC1PTPN1CYP19A1KDM4E
SCHEMBL16924700 0.79 VKORC1 (0.63) IKBKBVKORC1PDE4DPTPN1NUDT1
SCHEMBL2364536 0.78 KDM4E (0.45) KDM4EMEN1ALDH1A1CYP3A4HPGD
SCHEMBL5795210 0.77 NMUR2 (0.47) PTPN1KDM4EMEN1ALDH1A1CYP3A4
SCHEMBL290080 0.76 NMUR2 (0.71) KDM4EMEN1ALDH1A1CYP3A4HPGD
SCHEMBL31675811 0.76 NMUR2 (0.71) KDM4EMEN1ALDH1A1CYP3A4HPGD
SCHEMBL25196944 0.75 IKBKB (0.72) IKBKBVKORC1PTPN1NUDT1RELA
SCHEMBL7047705 0.75 CYP3A4 (0.59) IKBKBVKORC1PDE4DPTPN1NUDT1
SCHEMBL15328698 0.75 CA12 (0.52) KDM4EMEN1ALDH1A1CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114796194-A Application of DA adduct derived from Morus plant in preparation of beta-G inhibitor 澳门大学 2022-07-29 — — CN claimed
CN-110872267-A Compound extracted from paper mulberry and application of compound in preparation of protein tyrosine phosphatase 1B inhibitor 复旦大学 2020-03-10 — — CN claimed
US-20230190852-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH UNIGEN, INC. (US) 2023-06-22 — — US disclosed
CN-115950978-A Method for identifying flavonol novel compound in epimedium secondary metabolic pathway 重庆市中药研究院 2023-04-11 — — CN disclosed
CN-115364089-A Application of sanggenon C in preparing medicine for treating glioblastoma 西南大学 2022-11-22 — — CN disclosed
CN-114796194-A Application of DA adduct derived from Morus plant in preparation of beta-G inhibitor 澳门大学 2022-07-29 — — CN disclosed
CN-110872267-B Compound extracted from paper mulberry and application of compound in preparation of protein tyrosine phosphatase 1B inhibitor 复旦大学 2022-07-08 — — CN disclosed
CN-109207450-B Flavonoid isopentenyl transferase gene and application thereof 中国农业科学院北京畜牧兽医研究所 2022-04-15 — — CN disclosed
US-11123393-B2 Compositions and methods for joint health UNIGEN, INC. (US) 2021-09-21 — — US disclosed
CN-110872267-A Compound extracted from paper mulberry and application of compound in preparation of protein tyrosine phosphatase 1B inhibitor 复旦大学 2020-03-10 — — CN disclosed
EP-3010928-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH Unigen, Inc. (US) 2016-04-27 — — EP disclosed
US-20160067296-A1 Compositions and Methods for Joint Health UNIGEN, INC. (US) 2016-03-10 — — US disclosed
US-20150072953-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH UNIGEN, INC. 2015-03-12 — — US disclosed
WO-2014204866-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH UNIGEN, INC. (US) 2014-12-24 — — WO disclosed
WO-2003013554-A2 AROMATASE INHIBITORS FROM BROUSSONETIA PAPYRIFERA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2003-02-20 — — WO disclosed
US-6399579-B1 SOLVENT EXTRACTION; PLANT EXTRACTS HAUSER, INC. 2002-06-04 — — US disclosed
WO-2002013842-A1 COMPOSITIONS COMPRISING ICARISIDE I AND ANHYDROICARITIN AND METHODS FOR MAKING THE SAME HAUSER, INC. (US) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150072953-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH PTGES, PTGES3, PTGES2 IKBKB 174/4885VKORC1 269/4885PDE4D 1843/4885
US-11123393-B2 Compositions and methods for joint health PTGES, PTGES3, PTGES2 IKBKB 174/4885VKORC1 269/4885PDE4D 1843/4885
US-20160067296-A1 Compositions and Methods for Joint Health PTGES, PTGES3, PTGES2 IKBKB 174/4885VKORC1 269/4885PDE4D 1843/4885
US-20230190852-A1 COMPOSITIONS AND METHODS FOR JOINT HEALTH PTGES, PTGES3, PTGES2 IKBKB 174/4885VKORC1 269/4885PDE4D 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback